

## Healthcare & Life Sciences Practice

### Drug Pricing Digest

March 28, 2022 | Number 24

**Drug Pricing Initiatives:** Senators and stakeholders continue to discuss some of the drug price reform measures that were originally part of [H.R. 5376](#) (the Build Back Better Act, or BBBA), such as imposing price caps on prescription drugs through forced negotiation with the government. A particular focus in recent discussions appears to be the cost of insulin.

**Sources:** [Pink Sheet](#), Bloomberg Law ([link](#), [link](#), [link](#)), InsideHealthPolicy ([link](#), [link](#), [link](#), [link](#)), Politico Pro ([link](#), [link](#), [link](#)), [BioWorld](#), [Law360](#)

#### **MEDICAID DRUG REBATE PROGRAM (MDRP)**

No developments to report.

#### **340B PROGRAM**

**Contract Pharmacy Updates:** Two additional manufacturers have announced the implementation of contract pharmacy policies, bringing the total number of manufacturers that have done so to 16.

**Source:** 340B Report ([link](#), [link](#), [link](#))

**Additional States Seek to Regulate PBM 340B Activity:** Virginia and Nebraska have joined a dozen or so other states in seeking to regulate pharmacy benefit manager (PBM) actions related to the 340B program through state legislation. The Virginia General Assembly passed [HB 1162](#), while the Governor of Nebraska signed [Legislative Bill 767](#) into law.

**Source:** 340B Report ([link](#), [link](#))

#### **MEDICARE PART B**

**MedPAC Releases Annual Report:** The Medicare Payment Advisory Commission (MedPAC) released its annual [report](#) to Congress.

**Sources:** [Bloomberg Law](#), [InsideHealthPolicy](#)

#### **STATE LAW DEVELOPMENTS**

No developments to report.

---

If you have questions about the Drug Pricing Digest, please contact the Government Price Reporting team listed below or the Latham lawyer with whom you normally consult:

**Christopher H. Schott**

chris.schott@lw.com  
+1.202.637.2208  
Washington, D.C.

**Stuart S. Kurlander**

stuart.kurlander@lw.com  
+1.202.637.2169  
Washington, D.C.

**Eric C. Greig**

eric.greig@lw.com  
+1.202.637.3330  
Washington, D.C.

**James M. Deal**

jamie.deal@lw.com  
+1.202.637.2290  
Washington, D.C.

**Maria Malas**

maria.malas@lw.com  
+1.202.637.2334  
Washington, D.C.

**Lee B. Staley**

lee.staley@lw.com  
+1.617.880.4663  
Boston

The Drug Pricing Digest is published by Latham & Watkins as a news reporting service to clients and other friends. Sources listed in this digest cannot be supplied by Latham & Watkins LLP and may require subscription access. The information contained in this publication should not be construed as legal advice. Should further analysis or explanation of the subject matter be required, please contact the lawyer with whom you normally consult. The invitation to contact is not a solicitation for legal work under the laws of any jurisdiction in which Latham lawyers are not authorized to practice. A complete list of Latham's thought leadership publications can be found at [www.lw.com](http://www.lw.com). If you wish to update your contact details or customize the information you receive from Latham, [visit our subscriber page](#).

---